Horst J A
1 Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA.
Adv Dent Res. 2018 Feb;29(1):135-140. doi: 10.1177/0022034517743750.
Medical management of caries is a distinct treatment philosophy that employs topical minimally invasive therapies that treat the disease and is not merely prevention. This strategy is justified as an alternative or supplement to traditional care by significant disease recurrence rates following comprehensive operative treatment under general anesthesia. Silver diamine fluoride (SDF) is one agent to enable effective noninvasive treatment. The announcement of breakthrough therapy designation by the Food and Drug Administration (FDA) suggests that SDF may become the first FDA-approved drug for treating caries. Since our systematic review performed in April 2015, 4 clinical trials have been completed, which inform an update to the application protocol and frequency regimen. Suggestions from these studies are to skip the rinsing step due to demonstration of safety in young children, start patients with high disease severity on an intensive regimen of multiple applications over the first few weeks, and continue with semiannual maintenance doses as previously suggested. Breakthroughs in elucidating the impact of SDF on the dental plaque microbiome inform potential opportunities for understanding caries arrest. SDF can be added to the set of evidence-based noninvasive methods to treat caries lesions in primary teeth, such as the Hall crown technique and sealing lesions with accessible margins.
龋齿的医学管理是一种独特的治疗理念,采用局部微创疗法来治疗疾病,而不仅仅是预防。由于在全身麻醉下进行全面手术治疗后疾病复发率很高,这种策略被认为是传统治疗的替代或补充方法。氟化亚银(SDF)是一种能够实现有效非侵入性治疗的药物。美国食品药品监督管理局(FDA)宣布其具有突破性疗法认定,这表明SDF可能成为首个获得FDA批准用于治疗龋齿的药物。自我们在2015年4月进行系统评价以来,已完成4项临床试验,这些试验为应用方案和给药频率方案的更新提供了依据。这些研究的建议是,鉴于已证明对幼儿安全,可跳过冲洗步骤;对于疾病严重程度高的患者,在最初几周采用多次密集给药方案开始治疗,并如先前建议的那样继续每半年给予维持剂量。在阐明SDF对牙菌斑微生物群的影响方面取得的突破为理解龋齿的停止提供了潜在机会。SDF可以添加到基于证据的非侵入性方法中,用于治疗乳牙龋齿病变,如霍尔冠技术和封闭边缘可及的病变。